Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies

Molecular Medicine Today

Volumn 6, Issue 4, 2000, Pages 157-162

  Brown, J Martin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; HYPOXIA INDUCIBLE FACTOR 1; MITOMYCIN C; TIRAPAZAMINE;

ANIMAL CELL; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; GENE THERAPY; HUMAN; HYPOXIC CELL; METASTASIS; MOUSE; MUSCLE CRAMP; NONHUMAN; PROTEIN INDUCTION; REVIEW; SOLID TUMOR;

ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; NUCLEAR PROTEINS; RADIATION-SENSITIZING AGENTS; TRANSCRIPTION FACTORS; TRIAZINES; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0034176782     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(00)01677-4     Document Type: Review

References (32)

1. 2 histography. Vaupel P.W.et al. Tumor Oxygenation. 1995;219-232 Gustav Fischer Verlag, Germany.
2. Brown J.M. The hypoxic cell: a target for selective cancer therapy - 18th Bruce F. Cain Memorial Award lecture. Cancer Res. 59:1999;5863-5870.
3. Gray L.H.et al. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26:1953;638-648.
4. Nordsmark M.et al. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41:1996;31-40.
5. Brizel D.M.et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;285-289.
6. Fyles A.W.et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 48:1998;149-156.
7. Durand R.E. The influence of microenvironmental factors during cancer therapy. In Vivo. 8:1994;691-702.
8. Hockel M.et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515.
9. Brizel D.M.et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
10. Graeber T.G.et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
11. Reynolds T.Y.et al. Genetic instability induced by the tumor microenvironment. Cancer Res. 56:1996;5754-5757.
12. Blancher C., Harris A.L. The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metastasis Rev. 17:1998;187-194.
13. Lin A.J.et al. Potential bioreductive alkylating agents. 1. Benzoquinone derivatives. J. Med. Chem. 15:1972;1247-1252.
14. Rockwell S.et al. Mitomycin-C as a prototype bioreductive alkylating agent: in vitro studies of metabolism and cytotoxicity. Int. J. Radiat. Oncol. Biol. Phys. 8:1982;753-755.
15. Brown J.M., Siim B.G. Hypoxia-specific cytotoxins in cancer therapy. Semin. Radiat. Oncol. 6:1996;22-36.
16. Haffty B.G.et al. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 27:1993;241-250.
17. Zeman E.M.et al. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;1239-1242.
18. Wang J.et al. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 52:1992;4473-4477.
19. Delahoussaye Y.M.et al. Intranuclear metabolism of tirapazamine by matrix-associated reductases. Proc. Am. Assoc. Cancer Res. 38:1997;163. (Abstr. 1095).
20. Brown J.M., Lemmon M.J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 50:1990;7745-7749.
21. Dorie M.J., Brown J.M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 53:1993;4633-4636.
22. Kovacs M.S.et al. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br. J. Cancer. 80:1999;1245-1251.
23. von Pawel J., von Roemeling R. Survival benefit from tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: Final results from the international phase III CATAPULT 1 trial. Proc. Am. Soc. Clin. Oncol. 17:1998;454a. (Abstr. 1749).
24. Patterson L.H. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev. 12:1993;119-134.
25. McKeown S.R.et al. AQ4N: an alkylaminoanthraquinone N-oxides showing bioreductive potential and positive interaction with radiation in vivo. Br. J. Cancer. 72:1995;76-81.
26. Friery O.P.et al. Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br. J. Cancer. 2000;. (in press).
27. 2 homeostasis. Curr. Opin. Genet. Dev. 8:1998;588-594.
28. Maxwell P.H.et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275.
29. Trinh Q.T.et al. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res. 55:1995;4808-4812.
30. Shibata T.et al. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 2000;. (in press).
31. Brown J.M., Giaccia A.J. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 58:1998;1408-1416.
32. Brown J.M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer. 67:1993;1163-1170.